Clinigence Holdings Inc (NUTX)
NASDAQ:NUTX
Want to see NUTX full AI Analyst Report?
Top Page
Clinigence Holdings
(NASDAQ:NUTX)
Select Model
Select Model
Rating:77Outperform
Price Target:
$155.00
▼(-15.81% Downside)
Action:Reiterated
Date:05/10/26
The score is driven primarily by improved financial performance (profitability, strong growth, deleveraging, and robust cash flow) and an attractive low P/E valuation. Technicals are supportive with the stock trading above key moving averages, while the earnings call adds moderation due to significant near-term margin/IDR timing volatility and working-capital pressure.
Positive Factors
Revenue & Profitability
Sustained high revenue growth and restored positive margins signal a durable shift from prior loss years to profitable operations. This supports scalable earnings power, strengthens cash generation prospects, and provides a foundation for reinvestment and strategic expansion over the next 2–6 months.
Negative Factors
Margin Compression & EBITDA Decline
Sharp margin deterioration and a sizable EBITDA decline reveal structural cost pressures (facility costs, arbitration expenses, higher labor/supplies) that can erode sustainable profitability. If persistent, these dynamics could limit reinvestment capacity and pressure cash margins over the medium term.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue & Profitability
Sustained high revenue growth and restored positive margins signal a durable shift from prior loss years to profitable operations. This supports scalable earnings power, strengthens cash generation prospects, and provides a foundation for reinvestment and strategic expansion over the next 2–6 months.
Read all positive factors
Clinigence Holdings (NUTX) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$836.36M
Dividend YieldN/A
Average Volume (3M)182.88K
Price to Earnings (P/E)3.4
Beta (1Y)2.10
Revenue Growth40.95%
EPS Growth4.15%
CountryUS
Employees800
SectorHealthcare
Sector Strength45
IndustryMedical - Healthcare Information Services
Share Statistics
EPS (TTM)13.44
Shares Outstanding6,881,339
10 Day Avg. Volume136,993
30 Day Avg. Volume182,881
Financial Highlights & Ratios
PEG Ratio1.68
Price to Book (P/B)3.18
Price to Sales (P/S)1.20
P/FCF Ratio4.26
Enterprise Value/Market Cap1.03
Enterprise Value/Revenue0.98
Enterprise Value/Gross Profit2.07
Enterprise Value/Ebitda2.96
Forecast
1Y Price Target
$237.50Price Target Upside29.00% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)15.41
Revenue Forecast (FY)$883.02M
Clinigence Holdings Business Overview & Revenue Model
Company Description
Nutex Health, Inc. operates as a technology-enabled healthcare services company. It operates through two divisions: Hospital division and Population Health Management division. The Hospital division implements and operates health care models, incl...
How the Company Makes Money
The company generates revenue through its healthcare analytics platform, which is licensed to healthcare organizations such as physician groups, health systems, and accountable care organizations (ACOs). Additionally, Clinigence Holdings earns inc...
Clinigence Holdings Earnings Call Summary
Earnings Call Date:Apr 30, 2026
(Q1-2026)
| % Change Since: |
Next Earnings Date:Aug 06, 2026
Earnings Call Sentiment Neutral
The call presents a mixed picture: operationally and strategically Nutex demonstrates strong liquidity, improved net income, positive cash flow, active share repurchases, patient satisfaction, and a clear strategy to internalize development and scale population health. However, significant margin pressure and a 21% drop in adjusted EBITDA driven by higher facility costs and timing effects from IDR/arbitration recognition temper the results. Same-hospital revenue growth was minimal and accounts receivable rose, highlighting near-term execution and working capital considerations. Regulatory and arbitration accounting dynamics introduce additional volatility. Overall, positive cash generation and strategic initiatives are balanced by meaningful margin and accounting headwinds.Positive Updates
Revenue Growth
Total revenue of $216.5 million in Q1 2026, up ~2.2% year-over-year (from $211.8M in Q1 2025). Hospital division revenue grew to $207.6M (up 1.8% YoY) and same-hospital revenue was roughly flat (+0.2% YoY).
Negative Updates
Adjusted EBITDA Decline
Adjusted EBITDA fell to $57.6 million in Q1 2026 from $72.8 million in Q1 2025 — a decrease of $15.3 million or ~21% year-over-year, reflecting timing and cost impacts related to IDR/arbitration recognition.
Read all updates
Q1-2026 Updates
Positive
Negative
Revenue Growth
Total revenue of $216.5 million in Q1 2026, up ~2.2% year-over-year (from $211.8M in Q1 2025). Hospital division revenue grew to $207.6M (up 1.8% YoY) and same-hospital revenue was roughly flat (+0.2% YoY).
Read all positive updates
Company Guidance
Management guided that Nutex remains on track to expand meaningfully in 2026–27, reiterating plans to open three hospitals in Q3–Q4 2026 (San Antonio, Jacksonville and West Little Rock), to internally develop projects that typically take 18–24 months and cost roughly $20–$30 million apiece, and to target roughly 3–5 new hospitals per year while monetizing assets via sale‑leasebacks; they expect arbitration/IDR activity to normalize (currently submitting 50%–60% of claims, prevailing in >85% of determinations and collecting >80%, with arbitration-related costs currently higher at ~35% of arbitration revenue but expected to settle into a ~24%–26% range), signaled continued capital returns (completed $25M buyback retiring ~119k shares and initiated a second $25M program), and gave other forward-looking checkpoints including an effective tax rate in the high‑teens to ~20% range, ongoing investments in AI/IT and IPA insourcing, and reliance on a strong liquidity and balance sheet position (cash $207.3M, net cash from operations $75.5M, net long‑term debt down to $24.3M) alongside current operating metrics (Q1 revenue $216.5M, hospital revenue $207.6M, adjusted EBITDA $57.6M, net income $46.8M, visits 49,742 up 3.1%).Clinigence Holdings Financial Statement Overview
Summary
Income Statement
78
Positive
Balance Sheet
70
Positive
Cash Flow
82
Very Positive
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 879.95M | 875.26M | 479.95M | 247.65M | 219.29M | 331.53M |
| Gross Profit | 417.67M | 444.28M | 196.26M | 34.77M | 15.42M | 179.28M |
| EBITDA | 291.89M | 287.54M | 148.65M | -14.58M | -394.03M | 183.45M |
| Net Income | 96.38M | 70.79M | 52.18M | -45.79M | -424.78M | 132.59M |
Balance Sheet | ||||||
| Total Assets | 957.32M | 918.52M | 655.32M | 398.25M | 431.75M | 394.65M |
| Cash, Cash Equivalents and Short-Term Investments | 207.35M | 185.57M | 43.58M | 22.00M | 34.26M | 36.12M |
| Total Debt | 349.09M | 351.39M | 340.30M | 275.76M | 267.20M | 178.55M |
| Total Liabilities | 515.26M | 495.09M | 453.43M | 319.14M | 311.42M | 203.07M |
| Stockholders Equity | 346.29M | 329.45M | 146.34M | 61.45M | 95.86M | 114.65M |
Cash Flow | ||||||
| Free Cash Flow | 269.01M | 245.60M | 20.85M | -8.24M | 35.97M | 136.51M |
| Operating Cash Flow | 272.68M | 248.13M | 23.15M | 1.26M | 50.61M | 173.43M |
| Investing Cash Flow | -6.38M | -5.24M | -2.67M | -11.24M | -4.34M | -36.98M |
| Financing Cash Flow | -140.69M | -97.95M | 1.09M | -2.27M | -48.13M | -125.85M |
Clinigence Holdings Technical Analysis
Positive
184.11
Price Trends
109.11
Positive
123.15
Positive
118.68
Positive
Market Momentum
5.38
Positive
53.81
Neutral
23.36
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For NUTX, the sentiment is Positive. The current price of 184.11 is above the 20-day moving average (MA) of 124.91, above the 50-day MA of 109.11, and above the 200-day MA of 118.68, indicating a bullish trend. The MACD of 5.38 indicates Positive momentum. The RSI at 53.81 is Neutral, neither overbought nor oversold. The STOCH value of 23.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for NUTX.
Clinigence Holdings Risk Analysis
Clinigence Holdings disclosed 57 risk factors in its most recent earnings report. Clinigence Holdings reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
Clinigence Holdings Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
79 Outperform | $698.83M | 25.74 | 5.67% | 0.52% | 6.64% | 6.54% | |
77 Outperform | $836.36M | 3.40 | 31.39% | ― | 40.95% | 4.15% | |
56 Neutral | $3.04B | -50.55 | -2.86% | ― | 2.26% | 86.67% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
51 Neutral | $434.18M | -2.40 | -77.89% | ― | -21.26% | -290.08% | |
49 Neutral | $123.52M | -0.23 | -67.07% | ― | -3.89% | 63.03% | |
47 Neutral | $95.32M | -0.21 | -99.78% | ― | -2.83% | -223.32% |
* Healthcare Sector Average
NUTX
Clinigence Holdings
121.54
-47.46
-28.08%
HSTM
HealthStream
23.92
-4.16
-14.82%
EVH
Evolent Health
3.86
-4.14
-51.75%
HCAT
Health Catalyst
1.29
-2.45
-65.51%
TXG
10x Genomics
23.98
15.66
188.22%
DH
Definitive Healthcare Corp
0.86
-2.28
-72.64%
Clinigence Holdings Corporate Events
Executive/Board ChangesShareholder Meetings
Nutex Health Shareholders Approve Directors and Executive Pay
Positive
Apr 23, 2026
At its April 23, 2026 annual meeting, Nutex Health Inc. reported that shareholders representing about 69.29% of eligible common shares participated in voting, reflecting a solid quorum for corporate governance decisions. All seven director nominee...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.